Perspective Therapeutics Announces Collaboration Agreement Qith Bristol Myers Squibb To Evaluate [(212)Pb]VMT01 In Combination With Nivolumab In MC1R-Positive Metastatic Melanoma; Perspective Will Sponsor And Fund The Combination Study And Bristol Myers Squibb Will Provide Nivolumab For Use In The Study.
Portfolio Pulse from Benzinga Newsdesk
Perspective Therapeutics has entered into a collaboration agreement with Bristol Myers Squibb to evaluate [(212)Pb]VMT01 in combination with Nivolumab for treating MC1R-positive metastatic melanoma. Perspective will sponsor and fund the study, while Bristol Myers Squibb will supply Nivolumab.
March 18, 2024 | 12:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bristol Myers Squibb collaborates with Perspective Therapeutics to supply Nivolumab for a study on metastatic melanoma.
The collaboration with Perspective Therapeutics to supply Nivolumab for the study could enhance Bristol Myers Squibb's reputation in oncology and potentially lead to positive outcomes for its oncology portfolio, thus likely having a positive short-term impact on BMY's stock.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80